Eligible patients had initiated treatment and had 1 pharmacy claim of any dose strength of semaglutide 2.4 mg or tirzepatide in the US Komodo Health database between June 4, 2021 (approval date of semaglutide 2.4 mg), and December 15, 2023
It should look just like water
This compound is intended for controlled laboratory research focused on peptide-related cellular signalling, receptor interaction models, and molecular pathway analysis
English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP
Pins and needles, muscle weakness, recurring headaches, or feeling faint are all potential red flags